November 2025 OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi®in Non-Small Cell Lung Cancer
November 2025 OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
September 2025 Full renewal of the Board of Directors – Election of Dr. Markus Cappel as Chairman of the Board of Directors
September 2025 OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
September 2025 Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital – Clarification in Response to Unfounded Accusations
September 2025 Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting